VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 14, 2026

Stock Comparison

Agilent Technologies, Inc. vs AbbVie Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Agilent Technologies, Inc.

A · New York Stock Exchange

Market cap (USD)$42.1B
Gross margin (TTM)52.4%
Operating margin (TTM)21.3%
Net margin (TTM)18.8%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.

View A analysis

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$389B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

Comparison highlights

  • Moat score: both at 65 / 100.
  • Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); AbbVie Inc. has 6 segments (47.4% in Immunology).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; AbbVie Inc. has 3 across 2.

Primary market context

Agilent Technologies, Inc.

Agilent CrossLab

Market

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

Geography

Global

Customer

B2B (installed base labs across pharma, diagnostics, academia and applied markets)

Role

Aftermarket services + consumables + informatics

Revenue share

41.9%

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

Side-by-side metrics

Agilent Technologies, Inc.
AbbVie Inc.
Ticker / Exchange
A - New York Stock Exchange
ABBV - New York Stock Exchange
Market cap (USD)
$42.1B
$389B
Gross margin (TTM)
52.4%
n/a
Operating margin (TTM)
21.3%
n/a
Net margin (TTM)
18.8%
n/a
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
n/a
HQ country
US
US
Primary segment
Agilent CrossLab
Immunology
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
65 / 100
65 / 100
Moat domains
Demand, Supply
Legal, Demand
Last update
2025-12-22
2026-01-11

Moat coverage

Shared moat types

Brand Trust

Agilent Technologies, Inc. strengths

Design In QualificationInstalled Base ConsumablesService Field NetworkData Workflow Lockin

AbbVie Inc. strengths

IP Choke PointRegulated Standards Pipe

Segment mix

Agilent Technologies, Inc. segments

Full profile >

Life Sciences and Diagnostics Markets

Oligopoly

39.2%

Agilent CrossLab

Competitive

41.9%

Applied Markets

Oligopoly

18.9%

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.